Menu

Search

  |   Politics

Menu

  |   Politics

Search

Donald Trump comments on Pentagon UFO report

Joyce N. Boghosian (via Trump White House archive) / Wikimedia Commons

The US Defense Department is set to present its upcoming report on Unidentified Flying Objects this year. Former President Donald Trump weighed in on the upcoming report saying that he is not so much a believer in the phenomenon.

Trump addressed the upcoming report - which he ordered in the final weeks of his presidency as part of his coronavirus relief bill - when he appeared on Dan Bongino’s radio show. The Pentagon is set to present its findings to Congress in June. Trump’s comments also follow his predecessor Barack Obama voicing his support for the existence of life outside Earth in several interviews.

“I’m a believer in what you see, but there are a lot of people out there who are into that,” said the former president. The host then pressed Trump if it is true, to which the former president replied, “I’m not such a believer, but some people are, so I don’t want to hurt their dreams or their fears. It could be fears more than dreams.”

During an appearance on The Late Late Show with James Corden, Obama said that there are UFO sightings that could not be explained. Obama explained that there is video footage and records of unidentified objects flying in the skies. The former president also noted that there are people who are seriously investigating to look into what those UFOs are.

US President Joe Biden however, appeared to brush off the UFO reports when questioned by Peter Doocy of Fox News.

In other news, the drug cocktail that was used to treat Trump when the former president contracted COVID-19 in October, was finally launched in India this week. Pharmaceutical companies Roche India and Cipla announced Monday that the antibody cocktail Casirivimab and Imdevimab would be on sale for ₹59,750 per dose or over $800. Cipla would be marketing the drug and the second batch of the antibody cocktail would be made available by mid-June.

The antibody cocktail can treat patients who are at high risk and are suffering from a mild to moderate form of COVID-19. A statement by the company said that each pack can treat two patients.

  • Market Data
Close

Welcome to EconoTimes

Sign up for daily updates for the most important
stories unfolding in the global economy.